Changes in ghrelin concentrations one year after resective and non-resective gastric bypass: Associations with weight loss and energy and macronutrient intakes

Department of Nutrition, Faculty of Medicine, University of Chile, Santiago, Chile.
Nutrition (Impact Factor: 2.93). 02/2012; 28(7-8):757-61. DOI: 10.1016/j.nut.2011.11.004
Source: PubMed


Ghrelin is a potent stimulator of appetite and synthesized in the stomach. Its role in weight loss after gastric bypass (GBP) is still controversial. The aim of this study was to evaluate the relation between weight loss and food intake and between weight loss and changes in serum ghrelin concentrations 1 y after GBP with resection of the bypassed stomach (R-GBP) and without resection (NR-GBP).
Of 50 women (37.6 ± 10.2 y old, body mass index 43.8 ± 4.8 kg/m²) with GBP, 26 had R-GBP and 24 had NR-GBP. Body weight, body composition (dual energy x-ray absorptiometry), food intake, and serum ghrelin at baseline and 12 mo after GBP were measured.
The percentage of excess weight loss was 68.9 ± 12.8% at 12 mo after GBP. At 12 mo, the decrease of serum ghrelin was greater in the R-GBP group (-25.3 ± 22.5%) compared with the NR-GBP group (+11.2 ± 50.9%, P < 0.005). After adjustment by the baseline excess of body weight, there was a greater percentage of excess weight loss in the R-GBP group only at 6 mo (61.8% versus 54.9%, P = 0.011). After controlling for the baseline intake, a significant lower carbohydrate intake was observed in the R-GBP group 6 mo after surgery (P < 0.05).
A greater decrease in ghrelin levels was observed only in patients who underwent R-GBP at 12 mo after surgery. This difference was not associated with differences in dietary intakes or weight loss at the same time point. Therefore, the small gastric pouch is probably more important than decreased ghrelin levels in producing long-term weight loss after R-GBP.

Download full-text


Available from: Fernando Carrasco,
  • Source
    • "A strong association between ghrelin and extensive gastric atrophy in our study supports the suggested mechanism. The profound and long-term reduction of the serum ghrelin following resective gastric bypass is another evidence of gastric body mucosa serving as the main source of ghrelin which is eliminated by surgical resection rather than atrophic gastritis [26]. Moreover, long standing chronic inflammation of gastric mucosa with or without atrophic changes during H.pylori infection is associated with considerable reduction of fundic ghrelin mRNA expression and plasma ghrelin concentration [27], [28]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: A few studies have indicated inverse relationships between serum ghrelin and gastric and esophageal cancers but those associations have been restricted to specific populations, including smokers and overweight individuals. We examined the association between ghrelin and gastroesophageal cancers and atrophic gastritis in a population-based setting. In total 220 gastroesophageal cancers, comprising non-cardia and cardia gastric cancer, esophageal adenocarcinoma, esophageal squamous cell carcinoma (SCC) and age and gender-matched controls were recruited. Serum ghrelin, pepsinogen I/II ratio (PGI/II) and anti-H.pylori IgG antibodies were measured. Relationships between ghrelin and gastroesophageal cancers, after adjustment for PGI/II ratio, H.pylori status and smoking, were tested using logistic regression. Furthermore, in 125 endoscopically normal volunteers, with and without histological atrophic gastritis, the relationship with ghrelin was compared. Serum ghrelin (lowest vs. highest quintile) was inversely associated with gastric cancer: OR (95% CI) 8.71 (1.70-44.59) for cardia and 6.58 (1.26-34.46) for non-cardia cancer. Lower serum ghrelin was also associated with esophageal SCC: OR (95% CI) 5.69 (1.36-23.78), but not with esophageal adenocarcinoma. A similar association was observed between gastric cancer (cardia and non-cardia) and esophageal SCC when serum ghrelin was analysed as a continuous scaled variable. In endoscopically-normal volunteers, extensive atrophic gastritis was associated with low serum ghrelin [OR (95% CI) 0.25 (0.10-0.64)]. Inverse associations between ghrelin and some gastroesophageal cancers suggest a potential role for serum ghrelin as a biomarker of upper gastrointestinal cancers and atrophic gastritis. In areas with a high incidence of gastric and/or esophageal cancer, screening might be more effectively targeted to individuals with low serum ghrelin in addition to the PGI/II ratio.
    PLoS ONE 09/2013; 8(9):e74440. DOI:10.1371/journal.pone.0074440 · 3.23 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Roux-en-Y gastric bypass (RYGB) is the gold standard in bariatric surgery. The effect of the procedure is based on restriction, malabsorption and changes in hormonal axis. Ghrelin is an important appetite hormone which is produced mainly in the gastric fundus. By adding a resection of the gastric fundus, we hypothesized that excessive weight loss will be more prominent and the satiety feelings less pronounced compared to standard RYGB. A total of 73 patients with standard very very long limb (VVLL) RYGB (group A) were compared with 44 patients with VVLL RYGB with resection of the fundus (group B). Outcome measures were excessive weight loss (EWL), body mass index (BMI), early postoperative morbidity, change of co-morbidities, and appetite reduction as assessed by an appetite questionnaire over a postoperative period of 24 months. Groups were comparable in basic preoperative descriptions. Additional fundus resection did not influence EWL (group A 66.1 % vs. group B 70.6 %, p = 0.383) or BMI (group A 29 kg/m(2) vs. group B 27 kg/m(2), p = 0.199). No significant difference in morbidity or change of co-morbidities occurred. The appetite and satiety questionnaire showed no difference between group A and group B, respectively. Adding a resection of the gastric fundus in RYGB did not alter the clinical results, i.e., increased excessive weight loss, decrease of appetite, or increase of satiety. The value of removing a part of the ghrelin-producing cells might be overestimated.
    Obesity Surgery 11/2012; 23(3). DOI:10.1007/s11695-012-0805-y · 3.75 Impact Factor

  • Gastroenterology 05/2013; 144(5):S879. DOI:10.1016/S0016-5085(13)63268-0 · 16.72 Impact Factor
Show more